

Sanofi Patient Community Promise

September 2024



At Sanofi, we chase the miracles of science to improve people's lives. Our determination to find solutions for patients, caregivers, and families motivates us to develop breakthrough medicines and work tirelessly around the world to bring these innovations to patients and communities.

Sanofi is a company that listens, acts, and leads with the patient community¹. We are committed to dialogue and maintaining open lines of communication.

We continue to improve the quality of our engagement with patient communities grounded within and by the local environment and realities in which we work. We conduct ourselves in a manner reflective of individuals expectations to be seen, heard, and felt, and in a manner consistent with our ethical values.

Our commitment goes beyond our medicines. Sanofi recognizes that patients and individuals are more than their illness, disease, or vaccine interest, and we care about the broader, societal commitments of companies. We aim to build a healthier, more resilient world for our patients, communities, and our employees while minimizing the impact we, and our products, have on the planet.

This Promise deepens our commitments to the global patient communities we serve and formalizes our accountability in this regard. It was developed in collaboration with patients, caregivers, and patient advocacy organizations. As we continue to evolve both our commitment and our metrics to better monitor our progress², we always consult, involve, and work with these same communities.

1 *We develop medicines that reflect patient priorities*

Through collaborations with patients and caregivers, and by leveraging innovative, fit for purpose, real-world data, health related goals are identified and incorporated into our research and development programs.


- Sanofi's research is prioritized around the needs of the patient community.
- Our clinical studies are designed to reflect assessments and outcomes that

¹ Patient Community refers to the group that encompass: Patients, Patient Advocates, Patient Advocacy Groups, Caregivers and Families.

² First report in Q1 2025 for full year 2024.

matter most to patients and individuals, while making it easier for individuals to participate via remote and digital capabilities and reducing, where possible, the number of visits and procedures required.

The drug development process at Sanofi begins in the laboratory and continues until the safety and efficacy profile of the medicine is confirmed by the regulatory authorities and it becomes available to patients. At Sanofi we begin working closely with the patient community in late-stage research and continue engagement through clinical development.



We will report on the following metrics:

- Percent (%) of research programs where patient priorities are incorporated
- Percent (%) of development programs where patient priorities are incorporated
- Clinical trials demonstrate improved accessibility, inclusivity, and diversity through:
 - % of clinical trial designs informed by patient community insights
 - % of clinical trials that include remote and digital solutions that make it easier to participate
 - % of clinical trials achieving their diversity recruitment goals


2

We take a comprehensive approach to our partnership with the patient community

- We maintain lean, efficient internal policies and processes to appropriately engage and build partnerships with the patient community.
- We consistently train internal patient community engagement professionals at every level to ensure best-in-class execution.
- We engage in meaningful and timely dialogue with patient advocacy organizations on our science related to the disease area of interest for the organization.
- We partner with patient advocacy organizations on areas of shared policy interest.

- We design patient community programs and educational resources with patient community input either through meetings and dialogues or through formal collaborations.
- We collaborate with the patient community to identify and address barriers in the patient and caregiver pathways with respect to access to care and treatment.

As we continue to develop a medicine, our partnerships with the patient community grow.



We report on the following metrics:


- The number of employees trained on patient community engagement via in-person/ virtual learning or via online training platforms
- Performance as expressed by patient advocacy organizations in the annual Sanofi Partnership Quality Survey in the following categories:
 - Sanofi efforts on addressing healthcare policy, securing equitable access to medicines/immunizations, identifying and addressing unmet patient needs, understanding the patient's experience with the disease, supporting patient education and disease awareness, and engaging in scientific dialogue
 - Experience of working with Sanofi regarding: the relative ease of working together, having a clear point of contact, timeliness and relevance of communications, the process to submit funding requests, frequency of scientific updates, and collaborative engagement on shared topics of interest
 - Sanofi communications on its science, and support for access and patient focused healthcare policies
 - Contracting and/or funding request with Sanofi compared with other biopharmaceutical companies on system's ease of use, response time, and communications
- All financial interactions with patient advocacy organizations
- Qualitative reporting of key partnerships addressing areas of unmet need

3 *We advocate for people-centered health care systems*

We partner with the patient communities in the locations where we operate to advocate for public healthcare policies that prioritize patient insights and access to transformative medicines:

- We incorporate patient experience data in regulatory submissions and associated reimbursement dossiers.
- We commit to meaningful multi-stakeholder dialogue across all healthcare systems.

As we work with the external healthcare eco-system and seek to make a medicine available to patients, we ensure that patient priorities are reflected.




We report on the following metrics:

- Percent of regulatory filings where patient experience data has been submitted as evidence
- Percent of reimbursement dossiers where patient experience data has been submitted as evidence
- Number of Sanofi corporate advocacy or position papers and statements that are informed by patient communities

4 *We improve and adapt our medicines through real-world patient community insights*

- We continually enhance our medicines and associated devices where possible and relevant for patient communities based on feedback we receive.
- We generate ongoing insights and data, or evidence, on our medicines that is reflective of patient and caregiver interest and need.
- We partner with patient advocacy organizations to define data gaps and generate innovative patient experience data.

Once a medicine becomes available, our work continues to develop more knowledge about the medicine in a real-work setting.



We report on the following metrics:

- Number of actions taken following patient feedback on marketed medicines and devices
- Continued research on our marketed medicines and devices will be directly informed by the patient communities they are meant to serve and measured by percent of 'Integrated Evidence Generation Plans' that acted on patient community insight
- Qualitative reporting on real-world and patient experience data projects
- Number of advisory boards and/ or roundtable discussions with the patient and/or patient advocacy organizations

